CVM:NYSE.MKT

CEL-SCI Corporation

CEL-SCI Corporation is a Phase 3 cancer immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. The company is conducting a Phase 3 trial of Multikine (leukocyte interleukin injection) for the treatment of head-and-neck cancer in 17 countries. CEL-SCI is also developing treatments for HIV/HPV coinfected patients with anal warts in collaboration with the U.S. Navy at the San Diego Naval Medical Center through a cooperative research and development agreement. The company operates its own 75,000 sq ft manufacturing facility near Baltimore, MD.

Expert Comments:

Yale Jen, Laidlaw & Company (3/4/15)
"We are reassuming our coverage of CEL-SCI Corporation with a Buy rating and $6/share target price to reflect the advancements of Multikine in head and neck cancer. . .accelerating patient recuritment for the Multikine Phase 3 study is a positive development."

Robert Wasserman, Dawson James Securities (3/2/15)
"CEL-SCI Corporation shares already trade considerably below the average market capitalization and enterprise value for stocks with a cancer therapeutic in Phase 3 trials. In addition, the company has a number of other hidden assets that boost its value. . .we are initiating coverage on CEL-SCI shares with a Buy rating and 1218 month price target of $3/share."

Robert Wasserman, Dawson James Securities (2/20/15)
"CEL-SCI Corporation announced yesterday that the Ministry of Health for Malaysia has cleared that country for enrollment in the company's Phase 3 clinical trial of its Multikine immunotherapy treatment in head and neck cancer. Malaysia represents the twentieth country to approve the trial, with CEL-SCI targeting one more market for approval, or 21 total (including the U.S.)."

Management Q&A: View From the Top
Geert Kersten
Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited.
read more >
Dan Trang, Stonegate Capital Partners (2/11/15)
"CEL-SCI Corporation continues to enroll new patients for its Phase 3 Multikine trial, and recently expanded into the Philippines making it the 19th country to clear the Multikine trials. . .we believe the successful completion of the Phase 3 study is expected to enhance the value of CEL-SCI's business, going forward."

Acceleron Equity Research (1/12/15)
"In its Phase 3 trial for the treatment of head-and-neck cancer, the largest Phase 3 study for this indication in the world, CEL-SCI Corporation has executed on rapid acceleration in patient enrollment. The company reported an eight-fold increase in patient enrollment in 2014 over 2013 levels. Given the 800% increase in annual enrollment between 2013 and 2104, we assume CEL-SCI will comfortably complete enrollment in 2015."

Edward White, Laidlaw & Company (11/3/14)
"CEL-SCI Corporation announced the pricing of a secondary public offering and a registered direct offering for combined gross proceeds of approximately $7M. . .following the offering, we estimate the company has over $14M cash on its balance sheet. We are maintaining our Buy rating."

More Comments

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
CEL-SCI Corporation Content